Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Bob Swift who wrote (3089)	5/27/1999 8:06:00 PM
From: Mike McFarland	Respond to of 10280

Ah, for some reason I got it in my head that the parent drug company would only shell out royalties to SEPR on the ICE version til their parent drug went off patent. And maybe a few deals have been structured that way when it is expected that cheaper generics will move right in, but yes, I agree--and I should think for something like Xopenex, the generics would not have a chance. That said, I haven't yet tried Xopenex, and lately, using more steriods, I seem not to have to use my puffer and do not often get the heart palpitations I used to get... But what the patient thinks is hardly important--it is what Doctors (and in my case a nurse practitioner) are told to do by the HMO's --will they play it safe and always subscribe a safer drug if available, or will they go cheap? Looks like it is quite a mad race for Sepracor to get in there, skim revenue off a handful of existing blockusters, and also launch a few new blockbusters. Definately something to watch, and I'll certainly be watching developments on fluoxetine, saw a line about OCD in the slides, I am ever hopeful for those who suffer from that condition.